MedTrace Logo

A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

NCT05965089 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-12-06

No results posted yet for this study

Summary

The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of AX-202 infusion.

Conditions

  • Healthy Volunteers
  • Mild to Moderate Psoriasis

Interventions

BIOLOGICAL

Placebo

Placebo

BIOLOGICAL

AX-202

Humanized monoclonal antibody

Sponsors & Collaborators

  • Arxx Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05965089 on ClinicalTrials.gov